The class-action lawsuit alleges that Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca colluded in the summer of 2020 to restrict offering discounted products to 340B contract pharmacies.

The drugmakers should compete against each other, but instead “they worked together to boost their profits by coordinating to retract a long-standing discount for safety-net hospitals and clinics,” the lawsuit filed in the U.S. District Court for the Western District of New York said.

Mosaic argues that last summer the four drugmakers spent millions lobbying the federal government to limit 340B drug discounts for diabetes medicines such as insulin.

However, former President Donald Trump in July 2020 issued an executive order that aimed to ensure 1,000 community health centers would get insulin and injectable epinephrine at the 340B discounted rate.

While 340b is in effect, multiple drugmakers are allegedly moving to restrict the sale of insulin to healthcare providers at the reduced rate under the 340b program.